1. A physiologically relevant 3D collagen-based scaffold–neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models. (1st April 2018) Authors: Curtin, C.; Nolan, J.C.; Conlon, R.; Deneweth, L.; Gallagher, C.; Tan, Y.J.; Cavanagh, B.L.; Asraf, A.Z.; Harvey, H.; Miller-Delaney, S.; Shohet, J.; Bray, I.; O'Brien, F.J.; Stallings, R.L.; Piskareva, O. Journal: Acta biomaterialia Issue: Volume 70(2018) Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC. (23rd June 2022) Authors: Lee, E.; Matasar, M.; Conlon, R.; Mody, K.; Fiset, S.; Graff, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 2009 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗